Pazopanib in Molecularly Selected Patients With Advanced NSCLC

Summary

The purpose of this study is to evaluate how participants with advanced non-small cell lung cancer (NSCLC) that have certain abnormalities in the pazopanib target genes respond to pazopanib treatment.

Timeline

Start

2015-04-27

Primary completion

2019-12-24

Completion

2019-12-24

Outcome

Outcome not reported

Stopped: “Terminated by sponsor”

Drugs

Indications